159 related articles for article (PubMed ID: 29193566)
21. Mapping the incidence of drug-induced liver injury: A systematic review and meta-analysis.
Li M; Wang Y; Lv TT; Liu JM; Kong YY; Jia JD; Zhao XY
J Dig Dis; 2023 May; 24(5):332-339. PubMed ID: 37460777
[TBL] [Abstract][Full Text] [Related]
22. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents.
Devarbhavi H; Karanth D; Prasanna KS; Adarsh CK; Patil M
Hepatology; 2011 Oct; 54(4):1344-50. PubMed ID: 21735470
[TBL] [Abstract][Full Text] [Related]
23. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.
Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315
[TBL] [Abstract][Full Text] [Related]
24. Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs.
Hong H; Thakkar S; Chen M; Tong W
Sci Rep; 2017 Dec; 7(1):17311. PubMed ID: 29229971
[TBL] [Abstract][Full Text] [Related]
25. Assessment of case definitions for identifying acute liver injury in large observational databases.
Katz AJ; Ryan PB; Racoosin JA; Stang PE
Drug Saf; 2013 Aug; 36(8):651-61. PubMed ID: 23670723
[TBL] [Abstract][Full Text] [Related]
26. Review article: drug-induced liver injury in clinical practice.
Björnsson E
Aliment Pharmacol Ther; 2010 Jul; 32(1):3-13. PubMed ID: 20374223
[TBL] [Abstract][Full Text] [Related]
27. How to Diagnose and Exclude Drug-Induced Liver Injury.
Watkins PB
Dig Dis; 2015; 33(4):472-6. PubMed ID: 26159261
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Drug-Induced Liver Injury Developed During Hospitalization Using Electronic Health Record (EHR)-Based Algorithm.
Kang Y; Kim SH; Park SY; Park BY; Lee JH; An J; Won HK; Song WJ; Kwon HS; Cho YS; Moon HB; Shim JH; Yang MS; Kim TB
Allergy Asthma Immunol Res; 2020 May; 12(3):430-442. PubMed ID: 32141257
[TBL] [Abstract][Full Text] [Related]
29. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs.
Shimizu Y; Sasaki T; Takeshita JI; Watanabe M; Shizu R; Hosaka T; Yoshinari K
PLoS One; 2021; 16(6):e0253855. PubMed ID: 34170966
[TBL] [Abstract][Full Text] [Related]
30. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.
Chung CP; Rohan P; Krishnaswami S; McPheeters ML
Vaccine; 2013 Dec; 31 Suppl 10():K41-61. PubMed ID: 24331074
[TBL] [Abstract][Full Text] [Related]
32. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study.
Sobhonslidsuk A; Poovorawan K; Soonthornworasiri N; Pan-Ngum W; Phaosawasdi K
BMC Gastroenterol; 2016 Oct; 16(1):135. PubMed ID: 27793116
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review.
Wang R; Qi X; Yoshida EM; Méndez-Sánchez N; Teschke R; Sun M; Liu X; Su C; Deng J; Deng H; Hou F; Guo X
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):425-434. PubMed ID: 29323538
[TBL] [Abstract][Full Text] [Related]
34. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
35. Development of a Battery of
Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.
Aithal GP
Liver Int; 2015 Jul; 35(7):1801-8. PubMed ID: 25809692
[TBL] [Abstract][Full Text] [Related]
37. Prediction models for drug-induced hepatotoxicity by using weighted molecular fingerprints.
Kim E; Nam H
BMC Bioinformatics; 2017 May; 18(Suppl 7):227. PubMed ID: 28617228
[TBL] [Abstract][Full Text] [Related]
38. Hepatotoxicity by Drugs: The Most Common Implicated Agents.
Björnsson ES
Int J Mol Sci; 2016 Feb; 17(2):224. PubMed ID: 26861310
[TBL] [Abstract][Full Text] [Related]
39. Case definition and phenotype standardization in drug-induced liver injury.
Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
[TBL] [Abstract][Full Text] [Related]
40. Assessment of drug-induced liver injury in clinical practice.
Lucena MI; García-Cortés M; Cueto R; Lopez-Duran J; Andrade RJ
Fundam Clin Pharmacol; 2008 Apr; 22(2):141-58. PubMed ID: 18353109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
